Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07332091 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety of Vamifeport in Adult Participants With Homeostatic Iron Regulator Gene (HFE)-Related Hereditary Hemochromatosis
A Phase 2 study of Homeostatic Iron Regulator Gene-related Hereditary Hemochromatosis, sponsored by CSL Behring.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 84
- Enrollment target
- 20
- Study locations
NCT07332091: Recruiting Phase 2 study of Homeostatic Iron Regulator Gene-related Hereditary Hemochromatosis, sponsored by CSL Behring.
NCT07332091 is a Phase 2 study of Homeostatic Iron Regulator Gene-related Hereditary Hemochromatosis that is actively recruiting participants, run by CSL Behring. The registered enrollment target is 84 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (37% lower). The trial reports 20 study locations across 15 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07332091, a Phase 2 study of Homeostatic Iron Regulator Gene-related Hereditary Hemochromatosis, is actively recruiting participants, sponsored by CSL Behring.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 84 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a phase 2, multicenter, randomized, placebo-controlled, double-blind, parallel-group, proof-of-concept study to assess vamifeport in adult participants with homeostatic iron regulator gene-related hereditary hemochromatosis (HFE-HH). The primary objective of the study is to assess the effect of vamifeport treatment on magnetic resonance imaging (MRI)-based liver iron concentration (LIC) in adult participants with HFE-HH.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Vamifeport
Study Locations (20)
Maryland
- Johns Hopkins University School of Medicine - Baltimore
- American Oncology Partners, PA dba The Center for Cancer and Blood Disorders - Bethesda
- James M. Stockman Cancer Institute - Frederick
California
- Infinity Clinical Trials - San Diego
- Medical Oncology Associates of San Diego - San Diego
North Carolina
- University of North Carolina at Chapel Hill - Chapel Hill
- Duke University Medical Center (Duke South Clinics) -40 Duke Medicine Cir - Durham
Other
- Royal Brisbane and Women's Hospital - Brisbane
- Gallipoli Medical Research - Chandler
Arizona
- Banner MD Anderson - Gilbert
Florida
- Green Leaf Clinical Trials - Jacksonville
Indiana
- Indiana University Health University Hospital - Indianapolis
Louisiana
- Ochsner Medical Complex - High Grove - Baton Rouge
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 84 participants |
| Start Date | 2026-02-08 |
| Est. Completion | 2028-04-06 |
| Phase | Phase 2 |
What NCT07332091 shows while recruiting
NCT07332091 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 84 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (37% lower).
The record links to 1 condition, with Homeostatic Iron Regulator Gene-related Hereditary Hemochromatosis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07332091 names 20 study sites across 15 states, led by Maryland, California, North Carolina.
Frequently Asked Questions
What is clinical trial NCT07332091 about?
NCT07332091 is a clinical study titled "Efficacy and Safety of Vamifeport in Adult Participants With Homeostatic Iron Regulator Gene (HFE)-Related Hereditary Hemochromatosis". This is a phase 2, multicenter, randomized, placebo-controlled, double-blind, parallel-group, proof-of-concept study to assess vamifeport in adult participants with homeostatic iron regulator gene-related hereditary hemochromatosis (HFE-HH). The primary objective of the study is to assess the effect...
What is the current status of trial NCT07332091?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 84 participants. The study started on 2026-02-08. Estimated completion is 2028-04-06.
What conditions does trial NCT07332091 study?
This clinical trial studies the following conditions: Homeostatic Iron Regulator Gene-related Hereditary Hemochromatosis.
What interventions are being tested in trial NCT07332091?
The interventions under investigation include: Placebo (DRUG), Vamifeport (DRUG).
Who is sponsoring clinical trial NCT07332091?
This trial is sponsored by CSL Behring, which has 71 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07332091 being conducted?
This trial has 20 study locations across Arizona, California, Florida, Indiana, Louisiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07332091's enrollment target sits among peer trials
84 822nd of 2000 higher than 1,174 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02391519 · 84 participants
Effects of High Altitude on AMPK Activation
- NCT03838536 · 84 participants · NA
Synergistic Activity of Human Milk Nutrients and Infant Cognition
- NCT03884075 · 84 participants · Phase 2
Non-Alcoholic Fatty Liver Disease, the HEpatic Response to Oral Glucose, and the Effect of Semaglutide (NAFLD HEROES)
- NCT03894917 · 84 participants
Characterizing Disease Biology, Treatment and Toxicity in Older Adults With Hepatocellular Carcinoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI